Stephen Hennigan, MD
Infectious Disease · Fayetteville, ARNPI 1386728996
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,721 and has fallen 74.0% since, to $709 in 2025. Among infectious disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Cumberland Pharmaceuticals, Inc.$2K
- AbbVie$1K
- Insmed, Inc.$1K
- Gilead$1K
- Merck$583
- plus $2K from 15 others
What the payments were for
- Food & beverage$9,26199%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 91 | $1,674 |
| Cumberland Pharmaceuticals, Inc. | 33 | $1,608 |
| AbbVie(2 entities) | 80 | $1,271 |
| Insmed, Inc. | 60 | $1,180 |
| Gilead | 52 | $1,029 |
| Merck | 40 | $583 |
| Paratek Pharmaceuticals, Inc. | 15 | $402 |
| La Jolla Pharmaceutical Company | 21 | $372 |
| Astellas Pharma US Inc | 15 | $372 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $342 |
| Johnson & Johnson | 9 | $132 |
| Mayne Pharma Commercial LLC | 4 | $81 |
| Shionogi Inc | 4 | $72 |
| Pfizer | 4 | $68 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Nabriva Therapeutics, PLC | 2 | $36 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $27 |
| Theratechnologies Inc. | 2 | $26 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Octapharma USA, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,377 in reported general payments places this provider in the 90th percentile of 36 infectious disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 147 | $576,496 |
| JulucaDolutegravir/Rilpivirine | 35 | $122,494 |
| Daptomycin | 98 | $114,858 |
| DescovyEmtricitabine/Tenofov Alafenam | 45 | $99,206 |
| DovatoDolutegravir Sodium/Lamivudine | 34 | $98,969 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 19 | $67,074 |
| Isentress HdRaltegravir Potassium | 18 | $35,362 |
| IsentressRaltegravir Potassium | 12 | $25,198 |
| PifeltroDoravirine | 13 | $22,349 |
| ErtapenemErtapenem Sodium | 47 | $18,694 |
| CeftriaxoneCeftriaxone Sodium | 110 | $12,815 |
| Voriconazole | 18 | $8,456 |
| Vancomycin Hcl | 43 | $7,276 |
| Cefazolin Sodium | 49 | $4,153 |
| Cefepime Hcl | 11 | $2,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,029 | $675,701192 claims |
| Viiv Healthcare CompanyJuluca, Dovato, Triumeq | $1,674 | $288,53788 claims |
| MerckIsentress Hd, Isentress, Pifeltro | $583 | $82,91043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 infectious disease providers in Arkansas.
Other infectious disease in Fayetteville
- James NewtonFayetteville$15K
- Daniel YoungBentonville$65K
- Andrew EbersRogers$2K
- Jeremy BariolaLittle Rock$2K
- Kevin DavisFort Smith$2K
- Naveen PatilLittle Rock$1K
- Amanda NovackNorth Little Rock$1K
- Katherine FerrenLittle Rock$1K
- Mary BurgessLittle Rock$1K
- Jason HammackSherwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.